Vaccination against urinary tract infections caused by E. coli
暂无分享,去创建一个
[1] C. Alteri,et al. Quantitative Profile of the Uropathogenic Escherichia coli Outer Membrane Proteome during Growth in Human Urine , 2007, Infection and Immunity.
[2] G. Leverson,et al. Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial. , 2007, The Journal of urology.
[3] P. Schrotz-King,et al. Novel surface polypeptides of Campylobacter jejuni as traveller's diarrhoea vaccine candidates discovered by proteomics. , 2006, Vaccine.
[4] T. Hökfelt,et al. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection , 2006, Nature Medicine.
[5] A. Schaeffer,et al. Antigen-Specific Responses Accelerate Bacterial Clearance in the Bladder1 , 2006, The Journal of Immunology.
[6] C. Poh,et al. Identification of vaccine candidate antigens of an ESBL producing Klebsiella pneumoniae clinical strain by immunoproteome analysis , 2006, Proteomics.
[7] K. Brayton,et al. Identification of Novel Antigenic Proteins in a Complex Anaplasma marginale Outer Membrane Immunogen by Mass Spectrometry and Genomic Mapping , 2005, Infection and Immunity.
[8] H. Mobley,et al. Role of Motility in the Colonization of Uropathogenic Escherichia coli in the Urinary Tract , 2005, Infection and Immunity.
[9] H. Mobley,et al. The IrgA Homologue Adhesin Iha Is an Escherichia coli Virulence Factor in Murine Urinary Tract Infection , 2005, Infection and Immunity.
[10] B. Nowicki,et al. Vaccination with Purified Dr Fimbriae Reduces Mortality Associated with Chronic Urinary Tract Infection Due to Escherichia coli Bearing Dr Adhesin , 2005, Infection and Immunity.
[11] A. Schaeffer. A Toll-Like Receptor That Prevents Infection by Uropathogenic Bacteria , 2004 .
[12] D. C. Krause,et al. Predominant Outer Membrane Antigens of Bartonella henselae , 2004, Infection and Immunity.
[13] M. Chapman,et al. Antibody responses and protection from pyelonephritis following vaccination with purified Escherichia coli PapDG protein. , 2004, The Journal of urology.
[14] G. Wilding,et al. TheSiderophore Receptor IroN of Extraintestinal PathogenicEscherichia coli Is a Potential VaccineCandidate , 2003, Infection and Immunity.
[15] S. Hultgren,et al. Toll-like receptor 4 on stromal and hematopoietic cells mediates innate resistance to uropathogenic Escherichia coli , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[16] T. Russo,et al. IroN Functions as a Siderophore Receptor and Is a Urovirulence Factor in an Extraintestinal Pathogenic Isolate of Escherichia coli , 2002, Infection and Immunity.
[17] C. Tang,et al. Type 1 fimbriae and extracellular polysaccharides are preeminent uropathogenic Escherichia coli virulence determinants in the murine urinary tract , 2002, Molecular microbiology.
[18] A. Torres,et al. TonB-Dependent Systems of Uropathogenic Escherichia coli: Aerobactin and Heme Transport and TonB Are Required for Virulence in the Mouse , 2001, Infection and Immunity.
[19] J. R. Johnson,et al. Identification of a New Iron-Regulated Virulence Gene,ireA, in an Extraintestinal Pathogenic Isolate ofEscherichia coli , 2001, Infection and Immunity.
[20] T. Hooton,et al. Increasing Antimicrobial Resistance and the Management of Uncomplicated Community-Acquired Urinary Tract Infections , 2001, Annals of Internal Medicine.
[21] R. Conran,et al. Mutation of the Gene Encoding Cytotoxic Necrotizing Factor Type 1 (cnf1) Attenuates the Virulence of Uropathogenic Escherichia coli , 2001, Infection and Immunity.
[22] S. Hultgren,et al. Bacterial Invasion Augments Epithelial Cytokine Responses to Escherichia coli Through a Lipopolysaccharide-Dependent Mechanism1 , 2001, The Journal of Immunology.
[23] J. Sobel,et al. Urinary tract infection: self-reported incidence and associated costs. , 2000, Annals of epidemiology.
[24] A. Gooley,et al. Proteomic analysis of the Escherichia coli outer membrane. , 2000, European journal of biochemistry.
[25] J. Venter,et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. , 2000, Science.
[26] R Möllby,et al. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. , 2000, The Journal of infectious diseases.
[27] D. Uehling,et al. The urinary tract response to entry of pathogens , 1999, World Journal of Urology.
[28] M. Burdick,et al. Neutrophil recruitment and resistance to urinary tract infection. , 1999, The Journal of infectious diseases.
[29] S. Langermann,et al. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. , 1997, Science.
[30] L. Truong,et al. Development of experimental model of chronic pyelonephritis with Escherichia coli O75:K5:H-bearing Dr fimbriae: mutation in the dra region prevented tubulointerstitial nephritis. , 1997, The Journal of clinical investigation.
[31] C. Svanborg,et al. Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[32] S. Normark,et al. The Gal(alpha 1-4)Gal-specific tip adhesin of Escherichia coli P-fimbriae is needed for pyelonephritis to occur in the normal urinary tract. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[33] P. O'Hanley,et al. Alpha-hemolysin contributes to the pathogenicity of piliated digalactoside-binding Escherichia coli in the kidney: efficacy of an alpha-hemolysin vaccine in preventing renal injury in the BALB/c mouse model of pyelonephritis , 1991, Infection and immunity.
[34] M. Hanson,et al. Purification of the Escherichia coli type 1 pilin and minor pilus proteins and partial characterization of the adhesin protein , 1988, Journal of bacteriology.
[35] R. Freter,et al. Ascending, unobstructed urinary tract infection in mice caused by pyelonephritogenic Escherichia coli of human origin , 1983, Infection and immunity.
[36] L. Emödy,et al. Virulence of haemolytic strains of Escherichia coli in various animal models , 1982 .
[37] S. Falkow,et al. Haemolysin contributes to virulence of extra-intestinal E. coli infections , 1981, Nature.
[38] S. Hayakawa,et al. Survey of the susceptibility of urinary isolates to antibacterial agents in 2003 , 2005, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[39] H. Mobley,et al. Urinary tract infections : molecular pathogenesis and clinical management , 1996 .
[40] D. Uehling,et al. Resolution time of Escherichia coli cystitis is correlated with levels of preinfection antibody to the infecting Escherichia coli strain. , 1995, Urology.